#EGT European Green Transition PLC – Q1 2026 Operational Update April 9, 2026 – Posted in: European Green Transition Plc (EGT)

9 April 2026 – European Green Transition plc (AIM: EGT), a company operating in the critical infrastructure sector, provides an operational update on its Wind Energy Services business for the three months ended 31 March 2026 (“Q1 2026”). Further to EGT’s successful and oversubscribed £7.5 million fundraise and the completion of the acquisition of the Wind Energy Services business, the Company has had a positive start to 2026, with continued momentum across its repowering pipeline and order…

#HVO hVIVO PLC – >£5 million CRS contracts signed November 20, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September. The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS’ strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group’s sales pipeline…

#HVO hVIVO PLC – Notice of Results March 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2024 on Thursday 10 April 2025. Analyst briefing A briefing open to equity research analysts will take place on Thursday 10 April 2025 at 11.00am BST. To register and for more details please contact Walbrook PR on hvivo@walbrookpr.com. …

#HVO hVIVO PLC – Director/PDMR Shareholding March 7, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, was notified on 6 March 2025 that 6,440,119 options were exercised by Yamin Khan under the terms of the Company’s Long Term Incentive Plan (“LTIP”) at £0.001 per ordinary share. Of the 6,440,119 options exercised, Mr Khan has sold 3,062,246 ordinary shares of £0.001 each in the Company (“Ordinary Shares”) at 17p per Ordinary Share…

#HVO hVIVO PLC – £2m hMPV characterisation study contract February 17, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus (“hMPV”) characterisation trial announced in January 2025, it has signed a £2 million contract with a new biopharmaceutical client to complete the final stage of the characterisation study ahead of future hMPV human challenge trials (“HCTs”). The pilot characterisation trial produced a safe, measurable…

#HVO hVIVO PLC – £3.2m hLAB project January 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m. As part of this new contract, hLAB will act as the only contracted virology…

#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

#VELA investee co. #ENSI EnSilica PLC – New Contract for a Timing Controller ASIC December 6, 2024 – Posted in: Vela Technologies Plc (VELA)

EnSilica (AIM: ENSI), a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce that it has been awarded a contract for the design and supply of a precision timing controller ASIC to be used in high-value industrial test equipment products (the “Contract”). The total value of the Contract, including non-recurring engineering (“NRE”) and supply, is projected to exceed US$30m over 10 years, based on quoted NRE fees and the client’s…

#VELA investee co. #ENSI EnSilica PLC – Award of £2 million ASIC Design Services Contract October 21, 2024 – Posted in: Uncategorized

EnSilica, a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce that it has been awarded an ASIC design services contract with a prestigious supplier of power and propulsion systems used in the air, at sea, and on land (the “Contract”). The c.£2 million Contract will commence in November 2024, with revenues to run into the Company’s next financial year, supporting market expectations for both those periods. Ian…

#HVO hVIVO PLC – Long Term Incentive Plan/ PDMR Notification October 11, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted Yamin Khan, the Company’s Chief Executive Officer, and certain senior employees, a Long Term Incentive Plan (“LTIP”). The awards are intended to reward, incentivise and retain Mr Khan and certain senior employees to deliver sustainable growth for shareholders. Under the LTIP, Mr Khan has…